Therapeutic effects of γ-irradiation in a primary effusion lymphoma mouse model

Experimental and Therapeutic Medicine

Volumn 1, Issue 1, 2010, Pages 79-84

  Shiraishi, Yoshioki ^a   Gotoh, Kumiko ^a   Towata, Tomomi ^a   Shimasaki, Tatsuya ^a   Suzu, Shinya ^a   Kojima, Akihiro ^a   Okada, Seiji ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Animal model; Primary effussion lymphoma; Radiosensitivity

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASCITES; BONE MARROW TRANSPLANTATION; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRAIN K 562; CONTROLLED STUDY; GAMMA IRRADIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIMARY EFFUSION LYMPHOMA; RADIATION DOSE; RADIOSENSITIVITY; RAJI CELL; THERAPY EFFECT; TUMOR CELL LINE; WHOLE BODY RADIATION;

EID: 77955767524     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm_00000014     Document Type: Article

References (35)

1. Nador RG, Cesarman E, Chadburn A, et al: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88: 645-656, 1996.
2. Chen YB, Rahemtullah A and Hochberg E: Primary effusion lymphoma. Oncologist 12: 569-576, 2007.
3. Cesarman E, Chang Y, Moore PS, et al: Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186-1191, 1995.
4. Lee CK: Evolving role of radiation therapy for hematologic malignancies. Hematol Oncol Clin North Am 20: 471-503, 2006.
5. Gustavsson A, Osterman B and Cavallin-Stahl E: A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. Acta Oncol 42: 605-619, 2003.
6. Renne R, Zhong W, Herndier B, et al: Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat Med 2: 342-346, 1996.
7. Cesarman E, Moore PS, Rao PH, et al: Invitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood 86: 2708-2714, 1995.
8. Arvanitakis L, Mesri EA, Nador RG, et al: Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996.
9. Sellins KS and Cohen JJ: Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 139: 3199-3206, 1987.
10. Nicoletti I, Migliorati G, Pagliacci MC, et al: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279, 1991.
11. Shinkai Y, Rathbun G, Lam KP, et al: RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D) J rearrangement. Cell 68: 855-867, 1992.
12. Park SY, Saijo K, Takahashi T, et al: Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. Immunity 3: 771-782, 1995.
13. Attia MA and Weiss DW: Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain A mice infected with mammary tumor virus. Cancer Res 26: 1787-1800, 1966.
14. Harada H, Suzu S, Ito T, et al: Selective expansion and engraftment of human CD16+ NK cells in NOD/SCID mice. Eur J Immunol 35: 3599-3609, 2005.
15. Vermes I, Haanen C, Steffens-Nakken H, et al: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39-51, 1995.
16. Boulanger E, Daniel MT, Agbalika F, et al: Combined chemotherapy including high-dose methotrexate in KSHV/HHV8-associated primary effusion lymphoma. Am J Hematol73: 143-148, 2003.
17. Pauley JL, Panetta JC, Schmidt J, et al: Late-onset delayed excretion of methotrexate. Cancer Chemother Pharmacol 54: 146-152, 2004.
18. Waddington TW and Aboulafia DM: Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review. AIDS Patient Care STDS 18: 67-73, 2004.
19. Liu L, Eby MT, Rathore N, et al: The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 277: 13745-13751, 2002.
20. Chaudhary PM, Jasmin A, Eby MT, et al: Modulation of the NF-kappa B pathway by virally encoded death effector domains-containing proteins. Oncogene 18: 5738-5746, 1999.
21. Sun Q, Matta H and Chaudhary PM: The human herpes virus 8-encoded viral FLICE inhibitory protein protects against growth factor withdrawal-induced apoptosis via NF-kappa B activation. Blood 101: 1956-1961, 2003.
22. Mayo MW and Baldwin AS: The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470: M55-M62, 2000.
23. Keller SA, Schattner EJ and Cesarman E: Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96: 2537-2542, 2000.
24. Dabaghmanesh N, Matsubara A, Miyake A, et al: Transient inhibition of NF-kappaB by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. Cancer Sci 100: 737-746, 2009.
25. Keller SA, Hernandez-Hopkins D, Vider J, et al: NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas invivo. Blood 107: 3295-3302, 2006.
26. Takahashi-Makise N, Suzu S, Hiyoshi M, et al: Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma invitro and invivo and induces apoptosis via suppression of the NF-kappaB pathway. Int J Cancer 125: 1464-1472, 2009.
27. McConkey D, Nawrocki ST and Andtbacka R: Velcade displays promising activity in primary effusion lymphoma cells. Cancer Biol Ther 4: 491-492, 2005.
28. An J, Sun Y, Fisher M, et al: Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia 18: 1699-1704, 2004.
29. Boulanger E, Meignin V and Oksenhendler E: Bortezomib (PS-341) in patients with human herpesvirus 8-associated primary effusion lymphoma. Br J Haematol 141: 559-561, 2008.
30. Gospodarowicz M: Radiotherapy in non-Hodgkin lymphomas. Ann Oncol 19 (Suppl 4): 447-450, 2008.
31. Cassoni A, Ali U, Cave J, et al: Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. J Clin Oncol 26: 5297-5299, 2008.
32. Dubray B, Breton C, Delic J, et al: Invitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother Oncol 46: 185-191, 1998.
33. Bankert RB, Hess SD and Egilmez NK: SCID mouse models to study human cancer pathogenesis and approaches to therapy: potential, limitations, and future directions. Front Biosci 7: c44-c62, 2002.
34. Bankert RB, Egilmez NK and Hess SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 22: 386-393, 2001.
35. Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130, 2007.